<DOC>
	<DOCNO>NCT00004924</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel together irinotecan work treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Irinotecan Treating Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity toxicity irinotecan paclitaxel patient advance non-small cell lung cancer . OUTLINE : Patients receive paclitaxel IV 1 hour follow immediately irinotecan IV 30 minute . Treatment continue weekly 2 week follow one week rest . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 11-22 patient accrue study 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic nonsmall cell lung cancer curative therapy exist Stage IIIB pleural effusion allow Measurable evaluable disease CNS metastases allow disease stable least 4 week follow completion surgery and/or radiotherapy anticonvulsant require PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN tumor involve liver ) Renal : Creatinine clearance least 70 mL/min Other : No malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective birth control No active infection No concurrent medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy lung cancer No prior irinotecan paclitaxel Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior wide field radiotherapy No prior radiotherapy great 20 % bone marrow allow Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>